JP2023539390A5 - - Google Patents
Info
- Publication number
- JP2023539390A5 JP2023539390A5 JP2023537445A JP2023537445A JP2023539390A5 JP 2023539390 A5 JP2023539390 A5 JP 2023539390A5 JP 2023537445 A JP2023537445 A JP 2023537445A JP 2023537445 A JP2023537445 A JP 2023537445A JP 2023539390 A5 JP2023539390 A5 JP 2023539390A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073534P | 2020-09-02 | 2020-09-02 | |
| US63/073,534 | 2020-09-02 | ||
| PCT/CA2021/051214 WO2022047583A1 (en) | 2020-09-02 | 2021-09-02 | Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539390A JP2023539390A (ja) | 2023-09-13 |
| JPWO2022047583A5 JPWO2022047583A5 (https=) | 2024-09-04 |
| JP2023539390A5 true JP2023539390A5 (https=) | 2024-09-04 |
Family
ID=80492288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537445A Pending JP2023539390A (ja) | 2020-09-02 | 2021-09-02 | ニトロ化サイロシビン誘導体ならびに５－ｈｔ２ａ受容体を調節するためおよび精神障害を処置するためのその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230040398A1 (https=) |
| EP (1) | EP4208446A4 (https=) |
| JP (1) | JP2023539390A (https=) |
| KR (1) | KR20230061473A (https=) |
| CN (1) | CN116782896A (https=) |
| AU (1) | AU2021336667A1 (https=) |
| CA (1) | CA3191095A1 (https=) |
| IL (1) | IL301028A (https=) |
| MX (1) | MX2023002619A (https=) |
| WO (1) | WO2022047583A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114787363A (zh) | 2019-10-01 | 2022-07-22 | 恩派瑞安神经科学公司 | 对真菌进行遗传工程化以调节色胺表达 |
| EP4291549A4 (en) | 2021-02-12 | 2025-01-22 | Enveric Biosciences Canada Inc. | MULTISUBSTITUENT PSILOCYLYBINDER DERIVATIVES AND METHODS OF USE |
| EP4457336A4 (en) | 2021-12-31 | 2026-01-14 | Empyrean Neuroscience Inc | ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| EP4493544A4 (en) * | 2022-03-18 | 2026-03-04 | Enveric Biosciences Canada Inc | TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE |
| KR20250097973A (ko) * | 2022-11-18 | 2025-06-30 | 인베릭 바이오사이언시스 캐나다 인크. | 치환된 n-프로필아민 융합 헤테로사이클릭 메스칼린 유도체 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1083918A1 (en) * | 1998-06-08 | 2001-03-21 | Advanced Medicine, Inc. | Novel therapeutic agents that modulate 5-ht receptors |
| ES2172415B2 (es) * | 2000-07-28 | 2003-11-16 | Univ Madrid Complutense | Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. |
| KR20030046395A (ko) * | 2000-07-28 | 2003-06-12 | 인스파이어 파마슈티컬스 인코퍼레이티드 | 인돌 유도체를 사용하여 안압을 감소시키는 방법 |
| DE60222396T2 (de) * | 2001-03-29 | 2008-05-15 | Eli Lilly And Co., Indianapolis | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste |
| EP1747779A1 (en) * | 2005-07-28 | 2007-01-31 | Laboratorios Del Dr. Esteve, S.A. | Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands |
| CN103601662B (zh) * | 2013-11-21 | 2016-04-06 | 深圳市药品检验所 | 一种褪黑素半抗原、褪黑素完全抗原及其制备方法和应用 |
| WO2015140799A1 (en) * | 2014-03-18 | 2015-09-24 | Carmel-Haifa University Economic Corp. Ltd | Methods for improving cognitive function via modulation of quinone reductase 2 |
| EP3532492A4 (en) * | 2016-10-26 | 2020-10-14 | University of Florida Research Foundation, Incorporated | HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYZERS |
| WO2018106907A1 (en) * | 2016-12-08 | 2018-06-14 | Novatarg, Inc. | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therary |
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| US10640508B2 (en) * | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
-
2021
- 2021-09-02 EP EP21863154.7A patent/EP4208446A4/en active Pending
- 2021-09-02 MX MX2023002619A patent/MX2023002619A/es unknown
- 2021-09-02 WO PCT/CA2021/051214 patent/WO2022047583A1/en not_active Ceased
- 2021-09-02 IL IL301028A patent/IL301028A/en unknown
- 2021-09-02 AU AU2021336667A patent/AU2021336667A1/en not_active Abandoned
- 2021-09-02 KR KR1020237011175A patent/KR20230061473A/ko not_active Withdrawn
- 2021-09-02 CN CN202180068083.6A patent/CN116782896A/zh active Pending
- 2021-09-02 JP JP2023537445A patent/JP2023539390A/ja active Pending
- 2021-09-02 CA CA3191095A patent/CA3191095A1/en active Pending
-
2022
- 2022-09-09 US US17/941,531 patent/US20230040398A1/en active Pending